盐酸苯那普利药物上市后的流行病学监测

目的 评价盐酸苯那普利药品在以社区为基础的原发性高血压患者人群中使用的降压效果和安全性。方法 连续收集了１８３１例服用盐酸苯那普利药的原发性高血压患者的１８个月用药记录，包括血压水平、用药和不良反应情况等。结果 患者人群既往服药患者占１／３，按规定服药和单独服用盐酸苯那普利者占９６％以上。盐酸苯那普利的有效率从３个月的７３．６％上升到１８个月的８４．７％，各种特征的患者均有效。１８个月的血压下降幅

Evaluation on the effect of Benazepril for hypertension through postmarketing surveillance

Objective To evaluate the efficacy and safety of Benazepril used among the essential hypertensives. Methods 1 831 essential hypertensive patients aged 35 to 75 were randomly selected from a community and followed for 18 months. The level of blood pressure, status of taking Benazepril and side effects were sequencially collected. Results 1/3 of the patients had taken antihypertensive drug before the study and the rate of compliance was over 96%. The effective rate of Benazepril was 73.6 % at three months and increased to 84.7 % at 18 months. Comparing with the baseline data, SBP and DBP declined 10.8 mmHg and 6.7 mmHg respectively. The rate of side effect was 22.7 %. Cough was most commonly seen among side effects. The peak of first recording on side effect occurred at three months including 60% of them mild. Conclusion Results showed that Benazepril had good efficacy and safety for the essential hypertension patients in a long term observation.